Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
about
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsCYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewPharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsEfavirenz plasma concentrations and cytochrome 2B6 polymorphismsInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyEffect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV InfectionMight ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiPHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).Efavirenz in the therapy of HIV infection.CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsSecondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationHaplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Pharmacogenetic Optimization of Smoking Cessation Treatment.Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeClinically relevant genetic variations in drug metabolizing enzymes.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoPharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers
P2860
Q21245026-1BE88738-4E58-4352-BE28-65E0A399F6DFQ24606937-8B02115D-F15F-4DDF-B654-7F5231F3AD9AQ24609011-EF0455D0-420B-4F8F-9211-826670E7CC8EQ24633579-890F97D7-19B2-4FBB-9836-11C94F065993Q26797938-738121CC-DB4E-404C-9705-6E236FF3B97DQ28069383-4A9E38D8-ADD2-4D64-ACB5-29DF15DB7B8FQ28293288-EA55129A-BC6B-4CD5-BE2C-8F1A89881CFEQ28293875-43341C04-B8D5-4771-8894-6036C2F1DBBDQ28478666-A3C24F8C-57C8-42B9-8DC0-29EBE2F9BE2EQ28548638-1340AED4-9334-4F90-8E42-2A3F03A43D54Q28555028-440A755C-08D4-4EFD-AF0C-5B8AC0DAE063Q30438405-02DE7F07-D7A1-4E6A-8FD1-77277ADE2F1FQ31037300-FA8934B8-8AA1-4963-A2AC-776FA5C765CBQ33607011-1FDBA406-9AF3-4C68-80F9-4B69EF69CA28Q33623024-37E95D5E-EB41-4518-B909-D7C21699ACEDQ33809438-5D17285B-AE52-47E8-AB0A-43A3F99C8B87Q33909996-14450ADD-2B65-4B0B-B146-CC706D64B552Q33914723-901A3669-C15C-4366-AEB5-5AC8764C039AQ34015667-E6477655-DC6D-4CBC-BF39-C7E103C1C700Q34060396-003E4756-3797-43E4-8254-CC5D9C3A8A8BQ34310059-0E7A4DDF-1A15-4DF6-BCEC-006EAEDBEC94Q34443184-17170B40-2C1A-4389-B010-0CF703918A0CQ34542169-55DC3A84-241D-48EA-B6EF-B3812DE4F9D0Q34710641-E88D5B67-BA88-4166-842E-901B9A94F59EQ34737523-6A58E2E1-3624-489F-847D-821843467E98Q34763589-0FF90C4A-8A43-4CF3-9889-3CAEEE26A451Q34824471-86BF4F39-AC71-4C5F-8CB3-F9E5BEB4D9B7Q35032378-94DB3D81-C9A5-476D-8269-E38C15FEA287Q35364120-4B7C8739-E3EC-421A-9E4D-1617131A531DQ35408073-8A68A736-0678-43F3-9D6A-AD2A0CC38E8DQ35518558-C20C914E-1B50-4735-B6E7-945B6D176452Q35547723-3CC62EB6-C188-4ABE-AAB5-B4BBF5936340Q35584977-732AA43A-55CF-4CA6-820E-D3DB96A52019Q35647150-ADBD69AD-C16A-45DD-AF40-03CA5291633FQ35846143-3031A35E-7AB5-41CE-B402-A4F0DEEBFDAAQ35846912-BB1A042B-ED45-43F4-B568-FAF6E3F83066Q35878413-D751AAF9-41EC-4ECD-834B-0C0B8F309350Q36074119-AD917B04-D5A4-4C40-AF04-B33DC298AFA7Q36079108-99BEB739-8BF9-4720-9AFE-9F8A89FFD758Q36421698-3D6D6F57-844F-4F60-8823-13FB50433A6F
P2860
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Predictive value of known and ...... s in HIV-infected individuals.
@ast
Predictive value of known and ...... s in HIV-infected individuals.
@en
type
label
Predictive value of known and ...... s in HIV-infected individuals.
@ast
Predictive value of known and ...... s in HIV-infected individuals.
@en
prefLabel
Predictive value of known and ...... s in HIV-infected individuals.
@ast
Predictive value of known and ...... s in HIV-infected individuals.
@en
P2093
P2860
P50
P356
P1476
Predictive value of known and ...... ns in HIV-infected individuals
@en
P2093
J Blievernicht
M Eichelbaum
T Saussele
U M Zanger
P2860
P304
P356
10.1038/SJ.CLPT.6100072
P407
P577
2007-01-18T00:00:00Z